iTeos Therapeutics Inc.

Contributing Author

Recent Articles by iTeos Therapeutics Inc.

Jul-21	iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right GlobeNewswire
May-28	iTeos Therapeutics Announces Its Intention to Wind Down Operations GlobeNewswire
May-13	iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients GlobeNewswire